The study of the relationship between hepatic toxicity in hepatitis B virus markers seropositive cancer patients undergoing chemotherapy
- VernacularTitle:恶性肿瘤患者化疗后致肝损害与乙型肝炎病毒阳性的关联性探讨
- Author:
Wei MENG
1
;
Wanjun CAI
;
Guofeng SHAO
;
Cong WANG
;
Long SUN
Author Information
1. 辽宁省瓦房店中医医院综合病房
- Keywords:
Malignant tumor;
Chemotherapy;
HBV;
Hepatic toxicity
- From:
China Modern Doctor
2015;(13):91-93
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the relationship between the hepatic toxicity induced by chemotherapy in patients with malignant tumor who test positive for HBV markers. Methods From January 2008 to January 2014, 887 cancer patients were treated by chemotherapy. Among 274 cases of patients were HBV positive (positive group), 613 patients were HBV negative (negative group), the liver function after chemotherapy were compared. Results Positive group patients receiving chemotherapy had higher rate of hepatic toxicity than those in negative group (24.1% vs. 11.3%,P<0.01),the incidence rate of 3-4 grade hepatic toxicity in positive group patients was 11.2%(13/116),more than that in negative group 0.65%(4/613). In the different treatment, there were statistically significant in two groups by TP regimen(paclitaxel+cisplatin), CAF(cyclophosphamide+adriamycin+5-Fluorouracil), CHOP(cyclophosphamide+doxorubicin+oncovin+prednisone)liver function after chemotherapy (P<0.05). In the TP scheme leaded to the incidence of abnor-mal liver function was the highest, the incidence rate in positive group was 36%(18/50),the incidence rate in negative group was 15.8%(19/120). Conclusion HBV infection is associated with higher risk of hepatic toxicity in patients with malignant tumor during chemotherapy(led by TP scheme).
